Local injection of dsRNA targeting calcitonin receptor-like receptor (CLR) ameliorates Clostridium difficile toxin A-induced ileitis

Aditi Bhargava, University of California San Francisco
Matthew Clifton, Emory University
Pallavi Mhsake, University of California San Francisco
Min Liao, University of California San Francisco
Charalabos Pothoulakis, University of California Los Angeles
Susan E. Leeman, Boston University
Eileen F. Grady, University of California San Francisco

Journal Title: Proceedings of the National Academy of Sciences
Volume: Volume 110, Number 2
Publisher: National Academy of Sciences | 2013-01-08, Pages 731-736
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1073/pnas.1219733110
Permanent URL: https://pid.emory.edu/ark:/25593/s52f4

Final published version: http://dx.doi.org/10.1073/pnas.1219733110

Copyright information:
Copyright Bhargava et al.

Accessed December 27, 2018 11:28 AM EST
Local injection of dsRNA targeting calcitonin receptor-like receptor (CLR) ameliorates Clostridium difficile toxin A-induced ileitis

Aditi Bhargava a, Matthew S. Clifton b, Pallavi Mhaske a, Min Liao a, Charalabos Pouthoulakis c, Susan E. Leeman d,1 and Eileen F. Grady a,1

aDepartment of Surgery, University of California, San Francisco, CA 94143-0660; bSchool of Medicine, University of California, Los Angeles, CA 90095-7019; cDepartment of Surgery, Emory University, Atlanta, GA 30322; dDepartment of Pharmacology, Boston University, Boston, MA 02118-2526

Contributed by Susan E. Leeman, November 14, 2012 (sent for review April 27, 2012)

Enteritis caused by Clostridium difficile toxin (Tx) is a nosocomial disease of increasing clinical concern, but the local mediators of C. difficile TxA inflammation are unknown. The potent vasodilator calcitonin gene-related peptide mediates neurogenic inflammation via the calcitonin receptor-like receptor (CLR). Here we examined the ileum-specific effects of reducing CLR on TxA ileitis by local preinjection of double-stranded RNAs. Treatment with CLR dsRNA for 7 d decreased CLR immunoreactivity, whereas treatment with non-CLR dsRNA did not. Subsequent injection of TxA in the same location increased CLR in rats treated with non-CLR dsRNA but not in rats treated with CLR dsRNA, documenting that local injection of dsRNA is effective in preventing the increase in CLR immunoreactivity in response to local TxA. After non-CLR dsRNA pretreatment, TxA induced robust intestinal secretion, myeloperoxidase activity, and histopathologic indications of inflammation including epithelial damage, congestion, neutrophil infiltration, loss of mucin from goblet cells, and increase in mast cell numbers. After CLR dsRNA pretreatment, TxA-induced changes in intestinal secretion and histopathologic inflammation were improved, including normal mucin staining and fewer resident mast cells. Loss of CLR prevented TxA-mediated activation of NF-κB and concomitant increases in pERK1/2 and TNF-α mRNA. Locally produced CLR plays a proinflammatory role in TxA ileitis via MAPK signaling and TNF-α. The results reported here strongly suggest that a local injection of dsRNA targeting CLR could be an effective local therapeutic approach at the inflammation site in the treatment of a growing, clinically relevant hospital-acquired disease, C. difficile infection.

RNAi | nuclear translocation

The leading cause of diarrhea in hospitalized patients is Clostridium difficile infection due to antibiotic use (1). Toxin A (TxA) produced by C. difficile activates nuclear factor κB (NF-κB) and induces transcription of proinflammatory cytokines, including TNF-α and IL-8 (2). Intestinal inflammation induced by C. difficile TxA is characterized by neutrophil infiltration, intestinal secretion, and epithelial disruption, with a prominent neurogenic component (2–4).

A key player in neurogenic inflammation, calcitonin gene-related peptide (CGRP), is one of the most potent known vasodilators (5). The CGRP receptor is composed of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) (6). We developed highly specific antibodies that recognize CLR and RAMP1 and colocalized these components in the gastrointestinal tract and the spinal cord in rats (7, 8). CGRP and its receptors are expressed in distinct cell types in peripheral vs. central tissues, emphasizing the complexity of the CGRP/CLR/RAMP1 system (9). Identifying the peripheral function of these components is complex, because the peptide and its receptor are present both in intrinsic and extrinsic primary sensory afferent neurons (10, 11). Moreover, CGRP is produced by and activates migratory cells such as lymphocytes, granulocytes, and monococytes (12–14). Receptors for CGRP may be induced by intestinal inflammation, as is the substance P neurokinin 1 receptor in T cells and in intestinal epithelial cells (3, 15). Although systemic use of the peptide receptor antagonist CGRP-37 was shown to decrease TxA-induced inflammation (16), that study could not discriminate between the contributions made by central and ileal CGRP receptors to disease genesis or resolution.

In this report, to study whether ileally produced CLR has a role in C. difficile TxA enteritis, we injected dsRNA that targets CLR (CLR dsRNA) into the ileum of rats to transiently decrease the expression of CLR in the precise ileal segment where TxA would be injected at a later time. We determined whether local CLR is necessary and sufficient for C. difficile TxA to cause ileitis. We examined loss of mucin from goblet cells, mast cell recruitment, and the NF-κB, MAPK, and TNF-α signaling pathways, all of which are indices of C. difficile enteritis.

Results

Local Injection of CLR dsRNA in the Ileum Prevents TxA-Induced Increase in CLR Expression. To determine the role of local CLR in TxA enteritis, we decreased CLR expression in the rat ileum by RNA interference (RNAi) and verified this decrease by loss of immunoreactivity for CLR. Treatment with non-CLR dsRNA did not alter CLR immunoreactivity (CLR-IR), whereas, as expected, treatment with CLR dsRNA markedly decreased CLR-IR in the ileum (Fig. 1). The use of dsRNA caused no adverse effects, and body weight gains and losses were similar among all rats during the course of the study (Fig. S1).

After treatment for 7 d with CLR and non-CLR dsRNAs, we induced TxA ileitis. After 4 h of exposure to TxA, CGRP-IR in nerve fibers in the lamina propria increased strikingly (Figs. S2 and S3). At the same time, CLR-IR increased in nerve varicosities located near CGRP-IR in non-CLR dsRNA–treated rats (Fig. 1 and Fig. S2). Thus, the ligand and its receptor increased similarly during TxA-induced ileitis, and is a host response to the inflammatory insult. After pretreatment with non-CLR dsRNA and TxA treatment, CLR-IR was increased in nerve fibers and in neurons of the myenteric plexus, where it occasionally colocalized with the neuronal marker PGP9.5 (Fig. S3 D–O). The most prominent increase in CLR-IR occurred in nerve fibers of the lamina propria, where CLR-IR was colocaled with PGP9.5 (Fig. S3 P–T). Interestingly, CLR-IR was also detected in epithelial cells (Fig. 1 and Fig. S3 S–T). Remarkably, TxA treatment

Author contributions: A.B., S.E.L., and E.F.G. designed research; A.B., M.S.C., P.M., M.L., and E.F.G. performed research; C.P. and E.F.G. contributed new reagents/analytic tools; A.B., C.P., S.E.L., and E.F.G. analyzed data; and A.B., S.E.L., and E.F.G. wrote the paper.

The authors declare no conflict of interest.

To whom correspondence may be addressed. E-mail: sleeman@bu.edu or fgrady@alumni.ucsf.edu.

This article contains supporting information online at www.pnas.orglookup/suppl/doi:10.1073/pnas.1219733110/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1219733110

PNAS | January 8, 2013 | vol. 110 | no. 2 | 731–736
Local Injection of CLR dsRNA Decreases TxA-Induced Intestinal Secretion. To determine whether decreased CLR expression before induction of TxA ileitis affects TxA-associated secretory responses, we compared the weight of the closed loop (mg/cm), as an index of intestinal secretion, among naïve, non-CLR dsRNA-injected controls, and CLR dsRNA-injected rats. Local injection of dsRNA did not alter basal intestinal secretion, which was similar among the naïve and non-CLR dsRNA- and CLR dsRNA-treated rats (170 ± 21 vs. 168 ± 19 vs. 139 ± 2 mg/cm, respectively) (Fig. 2A). As expected, in the naïve and non-CLR dsRNA groups, TxA induced robust intestinal secretion (to 317 ± 68 and 345 ± 30, respectively). Thus, non-CLR dsRNA did not alter the inflammatory response to TxA. An interesting observation is that, although baseline secretion was not altered by the local injection of CLR dsRNA, when the tissue was challenged by injection of TxA there was a loss of function, with intestinal secretion decreased by 50% (to 226 ± 35 mg/cm) (Fig. 2A).

Local Injection of CLR dsRNA Decreases TxA-Induced Granulocyte Infiltration and Myeloperoxidase Activity. Pronounced neutrophil infiltration is a hallmark of inflammation induced by TxA. We determined whether the lack of CLR expression affects granulocyte infiltration. Treatment with vehicle in the non-CLR dsRNA and CLR dsRNA groups did not increase myeloperoxidase (MPO) activity, confirming that dsRNA treatment was not proinflammatory (Fig. 2B). As expected, treatment with TxA increased MPO activity fivefold in the loop fluid of the non-CLR dsRNA rats (622 ± 82 vs. basal levels of 128 ± 35 nU/mL). Pretreatment with CLR dsRNA decreased TxA-induced MPO activity by 40% compared with controls (367 ± 65 vs. basal levels of 113 ± 29 nU/mL) (Fig. 2B). Thus, locally produced CLR participates in the accumulation of granulocytes during TxA ileitis.

Local Injection of CLR dsRNA Decreases TxA-Induced Histopathologic Indication of Inflammation. We quantified changes in epithelial damage, edema and congestion, and granulocyte infiltration induced by TxA by scoring hematoxylin and eosin-stained sections. Pretreatment with non-CLR or CLR dsRNA did not change baseline histologic scores (Fig. 3A). TxA treatment increased epithelial damage, edema, and granulocyte infiltration in non-CLR controls (Fig. 3A). However, CLR dsRNA pretreatment reduced TxA-induced histopathologic inflammation compared with non-CLR controls (3.6 ± 0.5 vs. 6 ± 0.6, P < 0.05) (Fig. 3A).

Pretreatment with non-CLR or CLR dsRNA did not significantly affect baseline histologic architecture (Fig. 3B). As expected, TxA treatment induced histopathologic indications of inflammation in non-CLR dsRNA controls. Dilated blood vessels were prominent (Fig. 3B), with adherent neutrophils. Polymorphonuclear leukocytes and single epithelial cells were present in the lumen, compromising the epithelial integrity and exposing the lamina propria. Cellular infiltration markedly increased in the lamina propria. In contrast, pretreatment with CLR dsRNA decreased the TxA-induced histopathologic indications of inflammation (Fig. 3B). Preservation of epithelial architecture was the most significant change after CLR dsRNA pretreatment.

Local Injection of CLR dsRNA Decreases TxA-Induced Mucin Secretion. We previously found that loss of mucin in goblet cells accompanied TxA-mediated epithelial damage (17). Because epithelial architecture was preserved in rats pretreated with CLR dsRNA before TxA treatment (Fig. 3B), we examined mucin retention at the epithelial surface after TxA treatment. After vehicle treatment, intact goblet cells containing abundant mucin were evident in the epithelium of tissue from rats treated with non-CLR dsRNA or CLR dsRNA (Fig. 4A). TxA treatment induced a marked loss of mucin from goblet cells in the non-CLR dsRNA controls, most frequently at the tips of the villi (Fig. 4A). Secreted mucin was often detectable in the intestinal lumen. CLR...
dsRNA pretreatment prevented TxA-induced activation of goblet cells and loss of mucin, with little mucin evident in the lumen (Fig. 4A).

**Local Injection of CLR dsRNA Decreases TxA-Induced Mast Cell Recruitment.** Responses to TxA involve the recruitment of mast cells (2) that can secrete proteases and other inflammatory mediators that participate in the host response to TxA. Mast cell numbers were low after pretreatment with non-CLR or CLR dsRNA and vehicle (Fig. 4B). TxA increased mast cell numbers in the adjacent connective tissue in rats pretreated with non-CLR dsRNA (32.8 ± 9 vs. 9.7 ± 4 per field), and these cells were often degranulated (Fig. 4B and C). TxA failed to recruit mast cells after CLR dsRNA pretreatment; numbers were similar to those at baseline (12.4 ± 4 vs. 12.5 ± 5).

**Local Injection of CLR dsRNA Decreased TxA-Induced NF-κB and IκBα Expression.** The transcription factor NF-κB complexed with IκBα is present in the cytosol in an inactive state (18). Phosphorylation of IκBα results in the release of active NF-κB that translocates from the cytosol to the nucleus to activate transcription of a plethora of genes, including TNF-α. Western blot analysis showed that both IκBα and NF-κB were present at baseline (or after vehicle treatment of non-CLR dsRNA ileum) in the cytosolic fraction (Fig. 4C).

---

**Fig. 3.** Local injection of CLR dsRNA decreases histopathologic changes induced by TxA. A portion of loop tissue was sectioned and stained with hematoxylin and eosin. (A) Graphical representation of the histologic score is shown. Duplicate sections were scored for epithelial damage, edema and congestion, and neutrophil infiltration (0–5 per end point) (17). *P < 0.05 vs. vehicle, †P < 0.05 vs. rats treated with non-CLR dsRNA, followed by TxA treatment 7 d later. Values are mean ± SEM per loop, n = 8–12 loops per group. PMNs, polymorphonuclear leukocytes. (B) Pretreatment with CLR dsRNA minimized histopathologic indications of inflammation induced by TxA. In the non-CLR dsRNA controls, TxA induced severe damage (note dilated blood vessels; arrows). Pretreatment with CLR dsRNA preserved epithelial integrity even after TxA treatment (arrowheads). lp, lamina propria (n = 6–8 per group). (Scale bar, 100 μm.)

**Fig. 4.** Local injection of CLR dsRNA blocks goblet and mast cell involvement in TxA-induced enteritis. Triplicate sections were stained with Alcian Blue and Fast Red to identify goblet cell mucin, or toluidine blue to identify mast cells. (A) Pretreatment with CLR dsRNA decreased mucin loss due to TxA treatment. In areas adjacent to epithelial cell loss, TxA, but not vehicle, induced marked loss of mucin in goblet cells of rats pretreated with non-CLR dsRNA (arrows). (Scale bar, 100 μm.) (B) Pretreatment with CLR dsRNA prevented a TxA-induced change in mast cell numbers and appearance. In rats pretreated with non-CLR dsRNA, TxA induced mast cell accumulation in the mesenteric fat adjacent to the ileal loop (arrows). Often these cells were associated with dispersed metachromatic granules suggestive of degranulation. (Scale bar, 54 μm.) (C) Quantification of mast cells showed basal levels occurred after CLR dsRNA and TxA treatment. *P < 0.05 vs. vehicle, †P < 0.05 vs. rats pretreated with non-CLR dsRNA and treated with TxA. Values are mean ± SEM, n = 8–12 per group.
In this study, we examined the role of local CLR in C. difficile TxA ileitis, a clinically relevant model of neurogenic intestinal inflammation. We previously showed that CLR is required for functional responses to CGRP (20). CLR and RAMP1 comprise the CGRP receptor (6), and are colocalized throughout the gastrointestinal tract in nerve fibers and soma that may participate in TxA enteritis (7). We now show that TxA treatment increases CLR-IR as well as CGRP, and that local CLR is sufficient to mediate a host response to TxA. Local injection of dsRNA targeting CLR ameliorates the inflammatory responses to TxA by all variables examined, including intestinal secretion, MPO activity, loss of mucin, and mast cell infiltration. Pretreatment with CLR dsRNA decreases TxA-mediated histopathologic damage to about 50% of that seen in rats pretreated with non-CLR dsRNA; epithelial damage, edema/congestion, and neutrophil infiltration all decrease. The change in intestinal secretion, edema, and congestion suggests that locally produced CLR is sufficient to participate in vascular responses to TxA. Our results build upon the findings obtained with repeated

Local Injection of CLR dsRNA Decreased TxA-Induced MAP Kinase Activation. TxA activates MAP kinase signaling pathways during inflammatory insults, with ERK and p38 mediating monocyte necrosis, IL-1β release, and IL-8 gene expression (19). We examined pERK1/2 and ERK1/2 levels by Western blot analysis.

TxA increased pERK1/2 levels over vehicle treatment in the non-CLR dsRNA–pretreated rats (1.01 ± 0.07 vs. 0.23 ± 0.06, respectively) (Fig. 5E). Pretreatment with CLR dsRNA decreased the effect of TxA on pERK1/2, but did not alter basal levels of pERK1/2 (0.33 ± 0.09 vs. 0.23 ± 0.05, respectively). Thus, local CLR participates in TxA-induced MAP kinase activation, a signaling pathway that promotes inflammation in response to TxA.

Discussion

In this study, we examined the role of local CLR in C. difficile TxA ileitis, a clinically relevant model of neurogenic intestinal inflammation. We previously showed that CLR is required for functional responses to CGRP (20). CLR and RAMP1 comprise the CGRP receptor (6), and are colocalized throughout the gastrointestinal tract in nerve fibers and soma that may participate in TxA enteritis (7). We now show that TxA treatment increases CLR-IR as well as CGRP, and that local CLR is sufficient to mediate a host response to TxA. Local injection of dsRNA targeting CLR ameliorates the inflammatory responses to TxA by all variables examined, including intestinal secretion, MPO activity, loss of mucin, and mast cell infiltration. Pretreatment with CLR dsRNA decreases TxA-mediated histopathologic damage to about 50% of that seen in rats pretreated with non-CLR dsRNA; epithelial damage, edema/congestion, and neutrophil infiltration all decrease. The change in intestinal secretion, edema, and congestion suggests that locally produced CLR is sufficient to participate in vascular responses to TxA. Our results build upon the findings obtained with repeated

Local Injection of CLR dsRNA Decreased TxA-Induced TNF-α Expression. TxA mediates its inflammatory effects through induction of NF-κB, thereby increasing transcription of proinflammatory cytokines, including TNF-α (2). CLR’s role in TNF-α induction is unknown. TxA, but not vehicle, increased TNF-α mRNA levels after pretreatment with non-CLR dsRNA (1.6 ± 0.17 vs. 0.52 ± 0.22) (Fig. 5D). CLR dsRNA decreased TxA-induced TNF-α expression, but did not alter basal TNF-α expression (0.49 ± 0.11 vs. 0.50 ± 0.22). Thus, a local decrease in CLR is sufficient to prevent TxA induction of TNF-α expression.

Local Injection of CLR dsRNA Decreased TxA-Induced MAP Kinase Activation. TxA activates MAP kinase signaling pathways during inflammatory insults, with ERK and p38 mediating monocyte necrosis, IL-1β release, and IL-8 gene expression (19). We examined pERK1/2 and ERK1/2 levels by Western blot analysis.

TxA increased pERK1/2 levels over vehicle treatment in the non-CLR dsRNA–pretreated rats (1.01 ± 0.07 vs. 0.23 ± 0.06, respectively) (Fig. 5E). Pretreatment with CLR dsRNA decreased the effect of TxA on pERK1/2, but did not alter basal levels of pERK1/2 (0.33 ± 0.09 vs. 0.23 ± 0.05, respectively). Thus, local CLR participates in TxA-induced MAP kinase activation, a signaling pathway that promotes inflammation in response to TxA.

Discussion

In this study, we examined the role of local CLR in C. difficile TxA ileitis, a clinically relevant model of neurogenic intestinal inflammation. We previously showed that CLR is required for functional responses to CGRP (20). CLR and RAMP1 comprise the CGRP receptor (6), and are colocalized throughout the gastrointestinal tract in nerve fibers and soma that may participate in TxA enteritis (7). We now show that TxA treatment increases CLR-IR as well as CGRP, and that local CLR is sufficient to mediate a host response to TxA. Local injection of dsRNA targeting CLR ameliorates the inflammatory responses to TxA by all variables examined, including intestinal secretion, MPO activity, loss of mucin, and mast cell infiltration. Pretreatment with CLR dsRNA decreases TxA-mediated histopathologic damage to about 50% of that seen in rats pretreated with non-CLR dsRNA; epithelial damage, edema/congestion, and neutrophil infiltration all decrease. The change in intestinal secretion, edema, and congestion suggests that locally produced CLR is sufficient to participate in vascular responses to TxA. Our results build upon the findings obtained with repeated

Local Injection of CLR dsRNA Decreased TxA-Induced MAP Kinase Activation. TxA activates MAP kinase signaling pathways during inflammatory insults, with ERK and p38 mediating monocyte necrosis, IL-1β release, and IL-8 gene expression (19). We examined pERK1/2 and ERK1/2 levels by Western blot analysis.

TxA increased pERK1/2 levels over vehicle treatment in the non-CLR dsRNA–pretreated rats (1.01 ± 0.07 vs. 0.23 ± 0.06, respectively) (Fig. 5E). Pretreatment with CLR dsRNA decreased the effect of TxA on pERK1/2, but did not alter basal levels of pERK1/2 (0.33 ± 0.09 vs. 0.23 ± 0.05, respectively). Thus, local CLR participates in TxA-induced MAP kinase activation, a signaling pathway that promotes inflammation in response to TxA.

Discussion

In this study, we examined the role of local CLR in C. difficile TxA ileitis, a clinically relevant model of neurogenic intestinal inflammation. We previously showed that CLR is required for functional responses to CGRP (20). CLR and RAMP1 comprise the CGRP receptor (6), and are colocalized throughout the gastrointestinal tract in nerve fibers and soma that may participate in TxA enteritis (7). We now show that TxA treatment increases CLR-IR as well as CGRP, and that local CLR is sufficient to mediate a host response to TxA. Local injection of dsRNA targeting CLR ameliorates the inflammatory responses to TxA by all variables examined, including intestinal secretion, MPO activity, loss of mucin, and mast cell infiltration. Pretreatment with CLR dsRNA decreases TxA-mediated histopathologic damage to about 50% of that seen in rats pretreated with non-CLR dsRNA; epithelial damage, edema/congestion, and neutrophil infiltration all decrease. The change in intestinal secretion, edema, and congestion suggests that locally produced CLR is sufficient to participate in vascular responses to TxA. Our results build upon the findings obtained with repeated

Local Injection of CLR dsRNA Decreased TxA-Induced MAP Kinase Activation. TxA activates MAP kinase signaling pathways during inflammatory insults, with ERK and p38 mediating monocyte necrosis, IL-1β release, and IL-8 gene expression (19). We examined pERK1/2 and ERK1/2 levels by Western blot analysis.

TxA increased pERK1/2 levels over vehicle treatment in the non-CLR dsRNA–pretreated rats (1.01 ± 0.07 vs. 0.23 ± 0.06, respectively) (Fig. 5E). Pretreatment with CLR dsRNA decreased the effect of TxA on pERK1/2, but did not alter basal levels of pERK1/2 (0.33 ± 0.09 vs. 0.23 ± 0.05, respectively). Thus, local CLR participates in TxA-induced MAP kinase activation, a signaling pathway that promotes inflammation in response to TxA.
systemic injections of the peptide receptor antagonist CGRP8–37, and document a local site of action for CLR (16). Because the systemic approach did not yield an even greater effect, our results support the hypothesis that the major site of action of CLR in the response to TxA is local. Data also suggest that the TxA-induced increase in CLR-IR in the ileum promotes pathologic changes in the host, and that a local decrease of CLR can alter the outcome of TxA ileitis.

We found that a local decrease in CLR does not significantly alter basal levels of some end points examined, because there are factors other than CLR to mediate mucosal function. Differences in responses between rats pretreated with non-CLR dsRNA and rats pretreated with CLR dsRNA readily become manifest only after challenge with locally injected TxA, thereby documenting that the loss of CLR played a role in the response to TxA. Other experiments have shown that in diet-induced obesity, changes in macrophage function were revealed only after bacterial challenge (21). Lamina propria macrophages that were isolated from inflamed tissue had heightened TNF-α secretion, even without stimulation, suggesting that their environment altered their function (22). Thus, our finding that a role for CLR was only clearly demonstrated after inflammatory responses is paralleled by similar findings in other systems.

Because CGRP is a potent vasodilator (5), the effect of CLR dsRNA on vascular congestion was expected. It was unclear why CLR dsRNA decreased TxA-induced epithelial damage and neutrophil migration. After TxA binds to its receptor on monococytes, ERK1/2, NF-κB, and p38 MAP kinase are activated, leading to increased expression of proinflammatory cytokines that activate sensory nerves and recruit monocytes, mast cells, and neutrophils (2, 19). After a local injection of CLR dsRNA, TxA was unable to increase pERK1/2 or decrease NF-κB and IxBox protein expression in the cytosol. Decreased expression of phosphorylated IxBox in the cytosol is required to release NF-κB from the inactive complex. Our finding that loss of local CLR prevented TxA-mediated increase in cytosolic NF-κB and IxBox suggests that an increase in CLR expression is key for inflammatory mediators to initiate signaling cascades (such as MAPK/ERK) that in turn regulate NF-κB activation and cytokine production. Inability of NF-κB to translocate to the nucleus in turn prevented TxA-mediated increases in TNF-α. Thus, the proinflammatory pathway that leads to epithelial destruction and cell recruitment was decreased. These results clarify the mechanism of decreased epithelial cell damage and recruitment of monocytes and mast cells in rats pretreated with CLR dsRNA and injected with TxA.

C. difficile TxA induces a profound host response within 4 h, with a marked influx of granulocytes and profound epithelial changes. The TxA-induced increase in CLR-IR did not occur in rats pretreated with CLR dsRNA, providing a tool to study tissue-specific roles of genes in animals that are not easily amenable to genetic manipulation and without the caveat of developmental compensation. Compared with pharmacologic therapies that have variable on-target profiles and excretion rates, local decrease of gene expression enables a defined, clearly targeted therapy that minimizes potential side effects. As CGRP has diverse roles in different tissues (23–25), a targeted local delivery of dsRNA for CLR or CGRP is preferable. In agreement with previous findings, our dsRNA was not proinflammatory, because it did not alter weight gain or basal levels of intestinal secretion or cytokines and MPO activity (20, 26) and, importantly, CLR dsRNA specifically ameliorated TxA-induced ileitis. Because local injection of CLR dsRNA universally improved all end points of TxA-induced ileitis examined, our current findings suggest efficacy for encapsulated or luminal delivery of dsRNA to alter local inflammation in the gastrointestinal tract. This approach may be highly relevant, because C. difficile infections extend hospitalization (27).

A striking observation of the current study is the retention of normal epithelial architecture after TxA treatment in rats pretreated with CLR dsRNA. An early event in epithelial damage induced by TxA is the loss of mucin from goblet cells (2), which did not occur after pretreatment with CLR dsRNA. We have found that in TxA ileitis, protease-activated receptor 2 (PAR2) mice have an improved outcome and a minimal loss of mucin (17). CGRP can recruit mast cells to sites of inflammation (28) and, in response to TxA, mast cells can alter microvascular tone and promote fluid secretion (2). These results agree with our finding that locally produced CLR participates in TxA-induced mast cell recruitment and intestinal secretion.

In summary, we found that local injection of CLR dsRNA decreases CLR expression, which in turn is sufficient to prevent TxA-mediated increases in CLR and pathophysiologic responses to C. difficile TxA. Thus, local CLR has a striking proinflammatory role in host responses to TxA, and a local decrease of CLR offers a unique targeted therapy for C. difficile enteritis.

Materials and Methods

For antibodies and detailed experimental procedures, please refer to SI Materials and Methods.

Animals. Male Sprague–Dawley rats (n = 4–8 per group) weighing 250–280 g were individually housed in temperature- and light-controlled rooms, with ad libitum access to food and water. All procedures were performed in compliance with the Institutional Animal Care and Use Committee at the University of California, San Francisco.

Synthesis of dsRNA. dsRNA for CLR and control (globin) was prepared as described (20). Cloned cDNAs for CLR and globin were used as templates to transcribe sense and antisense RNAs in vitro using a MEGAscript RNA Kit (Ambion) as specified.

ileal Decrease of CLR with RNA Interference. Rats underwent anesthesia with isofluorane and a midline laparotomy. The terminal ileum was exteriorized and a marking suture was placed in the ileum (2 cm from the cecum). dsRNA (20 μg) for either β-globin (non-CLR dsRNA) or CLR (CLR dsRNA) was mixed with 1.5 μL of Lipofectamine 2000 (Invitrogen) and injected into the lumen as described by us previously (20).

C. difficile TxA Enteritis Model and Assessment of Inflammation. Seven days after dsRNA injections, purified TxA (5 μg) or vehicle (saline) was injected into a 4-cm ileal loop comprising the dsRNA injection site. Rats were euthanized 4 h after loops were formed. Loops were weighed and intestinal secretion was recorded (mg loop weight×cm loop length). Intestinal secretion was frozen for assay of neutrophil infiltration (myeloperoxidase, μU/mL). Tissue was frozen for RNA and protein analyses, or fixed in 10% (vol/vol) formalin and paraffin-embedded for histologic analysis or 4% (wt/vol) parafformaldehyde for immunoreactivity analysis. Naïve rats and rats injected with non-CLR dsRNA (20 μg in 200 μL) had similar responses to TxA, with identical intestinal secretion (2). Rats injected with non-CLR dsRNA were used as controls for all other end points examined.

Assessment of Histopathologic Changes. Paraffin-embedded sections (6-μm) were stained with hematoxylin and eosin. A histologist scored coded tissue sections for epithelial damage, congestion and edema, and neutrophil infiltration (0–5) (17).

Detection of Mucin and Mast Cells. Paraffin-embedded sections were stained with Alcian Blue pH 2.5 and Nuclear Fast Red (American MasterTech Scientific) to detect changes in goblet cell mucin. To detect connective tissue mast cells, sections were stained with 0.1% toluidine blue (pH 2.3) (Sigma) for 3 min.

Immunofluorescence Staining and Confocal Microscopy. A cross-section of loop tissue from rats treated with TxA or vehicle was fixed in 4% paraformaldehyde and stained for CLR using a rabbit antibody recognizing CLR (R11) and a mouse antibody recognizing CGRP (4901), as previously described (7); see SI Materials and Methods for details. Optical sections were acquired on a Zeiss LSM510 Meta microscope.
**RNA Analysis.** A portion of the ileal loop was homogenized, and RNA was isolated and analyzed as previously described (20); details of PCR primers are in SI Materials and Methods.

**Western Blot Analysis.** Total ileal protein (40 μg of total protein) was separated by SDS-PAGE, transferred to PVDF membranes (Immobilon−FL; Millipore), and incubated with antibodies to pERK1/2, ERK2, NF−κB, and IκBs and analyzed with the Odyssey Infrared Imaging System (LI-COR). See SI Materials and Methods for details.


**Statistical Analysis.** Data are shown as mean ± SEM. Differences among groups were analyzed by analysis of variance and Student–Newman–Keuls test or Bonferroni tests, as appropriate. Histologic assessment was analyzed by Mann–Whitney rank-sum test. A P < 0.05 was considered statistically significant.

**ACKNOWLEDGMENTS.** This project was supported by DK52387 (to E.F.G.), CCF1730 (to E.F.G.), DK080787 (to A.B.), DK080787-S2 (to A.B.), and DK47343 (to C.P.). M.S.C. was supported by National Institutes of Health Training Grant T32 DK07573.